Note: All changes are versus the prior-year period unless otherwise stated
CEO Paul Hudson noted that Sanofi's "business momentum has accelerated in the second quarter, delivering strong financial results driven by our core growth drivers Dupixent and vaccines." The executive added that the performance in the second quarter "gives us confidence in Sanofi's growth trajectory for this year."
Sanofi now expects business earnings per share to grow around 12% at CER, lifted from a prior estimate of an increase in the high-single digits.
The company reaffirmed that a Phase III study of SP0253, an adjuvanted recombinant-protein COVID-19 vaccine candidate being developed with GlaxoSmithKline, is on track to read out in the fourth quarter, with regulatory submissions to follow. "The potential need for booster shots is growing and there is a lot of interest in our COVID-19 vaccine programme from governments," noted chief financial officer Jean-Baptiste Chasseloup. He added that Sanofi also wants "to be in the race to see if mRNA can bring something to the flu market."
Meanwhile, Sanofi said it has dropped the complement C1s inhibitor sutimlimab from Phase I development in immune thrombocytopenic purpura, but did not give further details. The company also said it outlicensed SAR441236, a trispecific antibody in development for HIV, to ModeX Therapeutics except for some retained obligations related to the ongoing A5377 clinical trial sponsored by the US National Institutes of Health.
To read more Top Story articles, click here.